These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 35681233)

  • 1. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
    Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
    Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
    Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
    JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
    Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K
    J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.
    Yi Q; Liu C; Cui Y; Yang Y; Li Y; Fan X; Wu K
    Cancer Med; 2023 Mar; 12(6):6477-6487. PubMed ID: 37012831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
    BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older.
    Gu D; Wang T; Guo Y; Liu Y; Fang Y; Chen W; Wang Q; Zhang R; Shi H; Wu D; Zhang Z; Zhou G; Ye J
    Radiat Oncol; 2024 Aug; 19(1):112. PubMed ID: 39210445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
    Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
    Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M
    Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
    Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
    World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma.
    Jiang H; Li Q; Chen B; Xi M; Makelike K; Liu S; Hu Y; Zhu Y
    Cancer Med; 2023 Jul; 12(14):15187-15198. PubMed ID: 37334881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
    Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
    Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
    Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
    Xie C; Jing Z; Luo H; Jiang W; Ma L; Hu W; Zheng A; Li D; Ding L; Zhang H; Xie C; Lian X; Du D; Chen M; Bian X; Tan B; Xia B; Xie R; Liu Q; Wang L; Wu S
    Br J Cancer; 2020 Nov; 123(11):1616-1624. PubMed ID: 32958820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
    Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
    BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
    Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
    Chen B; Li Q; Li Q; Qiu B; Xi M; Liu M; Hu Y; Zhu Y
    Oncologist; 2020 Apr; 25(4):308-e625. PubMed ID: 31880371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.